Combined Analysis of Expression Profiles in a Mouse Model and Patients Identified BHMT2 as a New Regulator of Lipid Metabolism in Metabolic-Associated Fatty Liver Disease

Yongqiang Ma¹,², Zhi Tan³, Qiang Li¹,², Wenling Fan³, Guangshun Chen¹,², Yangyang Bin¹, Yi Zhou¹, Junfang Yi¹, Xiaohua Luo¹, Jieqiong Tan⁴, Zhongzhou Si¹,² and Jiequn Li¹,²*

¹Department of Liver Transplant, Second Xiangya Hospital, Central South University, Changsha, China, ²Transplant Medical Research Center, Second Xiangya Hospital, Central South University, Changsha, China, ³Department of Gastroenterology, The First Hospital of Changsha, Changsha, China, ⁴Center for Medical Genetics, School of Life Science, Central South University, Changsha, China

Metabolic associated fatty liver disease (MAFLD) is associated with obesity, type 2 diabetes mellitus, and other metabolic syndromes. Farnesoid X receptor (FXR, NR1H4) plays a prominent role in hepatic lipid metabolism. This study combined the expression of liver genes in FXR knockout (KO) mice and MAFLD patients to identify new pathogenic pathways for MAFLD based on genome-wide transcriptional profiling. In addition, the roles of new target genes in the MAFLD pathogenic pathway were also explored. Two groups of differentially expressed genes were obtained from FXR-KO mice and MAFLD patients by transcriptional analysis of liver tissue samples. The similarities and differences between the two groups of differentially expressed genes were analyzed to identify novel pathogenic pathways and target genes. After the integration analysis of differentially expressed genes, we identified 134 overlapping genes, many of which have been reported to play an important role in lipid metabolism. Our unique analysis method of comparing differential gene expression between FXR-KO mice and patients with MAFLD is useful to identify target genes and pathways that may be strongly implicated in the pathogenesis of MAFLD. The overlapping genes with high specificity were screened using the Gene Expression Omnibus (GEO) database. Through comparison and analysis with the GEO database, we determined that BHMT2 and PKLR could be highly correlated with MAFLD. Clinical data analysis and RNA interference testing in vitro confirmed that BHMT2 may a new regulator of lipid metabolism in MAFLD pathogenesis. These results may provide new ideas for understanding the pathogenesis of MAFLD and thus provide new targets for the treatment of MAFLD.

Keywords: FXR, metabolic associated fatty liver disease, transcription analysis, BHMT2, PPAR γ
INTRODUCTION

Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common among chronic liver diseases. It is diagnosed based on histological evaluation (biopsy), imaging studies, or blood biomarker evidence of fat accumulation in the liver (hepatic steatosis), in addition to one of the following three criteria: overweight/obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation (Eslam et al., 2020a). The pathogenesis and progression of MAFLD involve multiple factors, including insulin resistance, hormones secreted from adipose tissue, nutritional factors, gut microbiota, endoplasmic reticulum (ER) stress, innate immunity, genetic factors, and epigenetic factors (Tilg and Moschen, 2010; Buzzetti et al., 2016). MAFLD is a progressive disease. Most MAFLD patients have progressed from a simple steatosis to the more advanced form of the disease, which may ultimately lead to cirrhosis or hepatocellular carcinoma and liver decompensation.

MAFLD is the most common cause of cirrhosis and the current leading indication for liver transplant in women and the second leading cause in men (Ogawa et al., 2019). In addition to liver transplantation, there are no effective therapies for advanced MAFLD that have been approved by the Federal Drug Administration (FDA) or European Medicines Agency (EMA); thus, it is crucial to explore the pathogenesis of MAFLD.

Farnesoid X receptor (FXR) is a ligand activated transcription factor that belongs to the nuclear receptor (NR) superfamily (Forman et al., 1995), and is mainly expressed primarily in the liver, intestine, and kidney, while bile acids (BAs) are its endogenous ligands. FXR mainly functions as the BA sensor by regulating genes that are critically involved in BA homeostasis, including BA biosynthesis, conjugation, and enterohepatic circulation (Sinal et al., 2000). Furthermore, FXR activation leads to the expression of various genes involved in glucose, lipid, lipoprotein metabolism, and bile acid synthesis (Kunne et al., 2014). Hepatic FXR can inhibit lipid uptake and synthesis and can enhance β-oxidation, thus reducing liver lipid accumulation. Therefore, FXR also plays a crucial role in the treatment of MAFLD. Obeticholic acid (OCA), a first-generation FXR agonist, has been applied in clinical practice and has achieved good clinical effects, the development of second-generation FXR agonists is currently ongoing (Ogawa et al., 2019). Nonbile acid FXR agonists with a high affinity for intestinal FXR have been developed as new-generation FXR agonists (Tully et al., 2017).

In the present study, we applied a unique analysis method to obtain 134 overlapping genes by comparing the differential gene expression in liver tissue of FXR-KO mice and MAFLD patients, and a series of signaling pathways and molecules have also been identified through differential gene expression analysis. Furthermore, in conjunction with the GEO datasets, we identified two specific overlapping genes BHMT2 and PKLR differentially expressed in both models. The correlation analysis of clinical data and RNA interference further confirmed the correlation between BHMT2 expression and hepatocyte lipid metabolism. The result of real-time PCR showed that BHMT2 could affect hepatocyte lipid metabolism by regulating PPARG expression. Thus, we propose BHMT2 as a potential regulator of lipid metabolism associated with MAFLD.

MATERIALS AND METHODS

Clinical Samples and Patient Data

In this study, we included nine healthy control samples from adult patients who underwent surgical resection for hemangioma, and seven liver samples that were histologically diagnosed as MAFLD. Two experienced pathologists, blinded to clinical data, independently evaluated all liver samples according to the NAFLD activity score (NAS), defined as the sum of steatosis, inflammation, and ballooning of hepatocytes. Patients with a NAS score ≥5 were considered likely to have steatohepatitis (Kleiner et al., 2005). The clinical characteristics of the MAFLD and control groups are shown in Table 1.

Hepatic Transcriptome

Total RNA was extracted from liver tissue samples obtained from patients with MAFLD and healthy controls using the Illustra RNA spin Mini Kit (GE Healthcare, United States). RNA samples were quantified using a Nanodrop instrument (Thermo Fisher Scientific, United States) and qualified by agarose gel electrophoresis. Illumina kits which include procedures of RNA fragmentation, random hexamer primed first-strand cDNA synthesis, dUTP-based second strand cDNA synthesis, end-repairing, A-tailing, adaptor ligation, and library PCR amplification, were used for RNA-seq library preparation. Finally, the prepared RNA-seq libraries were qualified using a 2100 Bioanalyzer (Agilent, United States) and quantified using a qPCR absolute quantification method. The sequencing was performed using the Illumina Hi Seq 4000 platform. Raw sequencing data that passed the Illumina quality filter were used for the following analysis. Trimmed reads are aligned with the reference genome (Human GRCh38/hg38). Based on alignment statistical analysis (mapping ratio, rRNA/mt RNA content, and fragment sequence bias), we determined whether the results could be used for subsequent data analysis. After the livers of FXR-KO mice and control were obtained, hepatocyte RNA was extracted by the same method. Subsequently, expression profiling, differentially expressed genes, and differentially expressed transcripts were calculated. Genes with a p-value < 0.05 were considered differentially expression genes. Principal component analysis (PCA), correlation analysis, hierarchical clustering, gene ontology (GO), and pathway analysis were performed to explore the potential role of differentially expressed genes using R or the Python environment for statistical computing and graphical representation, respectively.

Animal Studies

C57/BL/6 mice were obtained from the Animal Research Center of Xiangya Medical College and we successfully constructed the FXR-knockout model mice (C57BL/6 FXR-/- mice were generated using the CRISPR/Cas9 system). Eight-week-old...
male wild-type (WT) and FXR-KO mice were fed a high-fat diet (HFD) (Bio Serv) for 16 weeks. All mice were housed under specific pathogen-free and controlled temperature conditions with a 12-h light-dark cycle at 22–24°C. Only male mice were used for the experiments. All animal studies were approved by the Animal Care and Use Committee of Central South University and were carried out according to the Guide for the Care and Use of Laboratory Animals.

**Immunohistochemistry**

Paraffin-embedded sections (5 μm) from each tissue were stained using immunohistochemistry with anti-BHMT2 or anti-PKLR antibodies (Sigma, United States). After deparaffinization, the sections were first incubated with 10% of normal goat serum in PBS for 1 h, and incubated with the primary antibodies overnight at 4°C. After washing twice and three times again. Approximately, 10% of the cells with high or low fluorescence intensity were sorted and collected using a fluorescence-activated cell sorter (BD Bioscience, United States).

**Immunoblotting**

CGI-58 antibody was purchased from Abcam. β-actin antibody was obtained from Cell Signaling Technology. Cells were lysed with lysis buffer containing 2% SDS, 62.5 mM Tris-HCl pH 6.8, and 10% glycerol. Protein concentrations were measured using a BCA kit and a protein standard. Subsequently, the samples were separated by SDS-PAGE and transferred to Immobilon-P polyvinylidene fluoride membranes (Millipore Corporation, Billerica, MA, United States). The membrane was blocked by incubating in 5% of defatted milk for 1 h, and incubated with the primary antibodies overnight at 4°C. After incubation, the membrane was washed three times for 30 min each and subsequently incubated with horseradish peroxidase-conjugated secondary antibodies. Visualization of target protein was achieved through Immobilon Western Chemiluminescent HRP substrate (Millipore Corporation, Billerica, MA, United States).

**Data and Statistical Analysis**

Pathway enrichment and GO analysis were performed using the web application Metascape and DAVID with analyses including “GO Biological Processes” and “KEGG Pathway” as the default parameters. Protein-protein interaction (PPI) enrichment analysis was carried out using STRING and Cytoscape. The resultant network contained a subset of proteins that form physical interactions with at least one other member in the list. If the network contained between 3 and 500 proteins, the molecular complex detection (MCODE) algorithm was applied to identify the densely connected components of the network. Pathway and process enrichment analysis was applied to each MCODE component independently using Metascape, and the three best-scoring terms defined by the p-value were retained as the functional description of the corresponding components.

Then, we queried the GEO database from National Center for Biotechnology Information (NCBI) and extracted two data sets for

---

**TABLE 1 | Clinical characteristics of MAFLD and control groups.**

| NO | Sex | Age (year) | BMI (kg/m²) | ALT (U/L) | ALP (U/L) | GGT (U/L) | TC (mmol/L) | TG (mmol/L) | HDL-C (mmol/L) | LDL-C (mmol/L) | FBG (mmol/L) | UA (μmol/L) | MetS | Diabetes | Hypertension | NAS |
|----|-----|----------|-------------|----------|---------|---------|-----------|-----------|-------------|-------------|-------------|------------|-------|------|--------|---------|-----|
| 1  | M   | 42       | 237.2       | 183.7    | 110.5   | 119.4   | 6.77      | 2.45      | 1.14        | 3.97        | 5.5         | 543.64     | +    | –    | +      | 6       |
| 2  | M   | 40       | 30.5        | 49.4     | 93.7    | 78.4    | 6.62      | 2.07      | 0.95        | 4.18        | 6.2         | 518.76     | +    | +    | +      | 5       |
| 3  | M   | 37       | 30.4        | 25       | 56.7    | 44.7    | 5.68      | 1.98      | 0.92        | 2.75        | 6.8         | 481.7      | +    | –    | –      | 5       |
| 4  | M   | 46       | 22.5        | 100.7    | 98.4    | 113.4   | 4.98      | 1.54      | 1.26        | 2.78        | 6.7         | 456.78     | –    | +    | +      | 4       |
| 5  | M   | 50       | 22.2        | 25.3     | 47.6    | 48.6    | 6.02      | 1.93      | 1.04        | 3.65        | 7.3         | 506.71     | +    | +    | +      | 5       |
| 6  | M   | 54       | 27.8        | 27.8     | 47.4    | 38.8    | 5.1       | 1.68      | 1.21        | 2.87        | 5.1         | 437.14     | –    | –    | +      | 4       |
| 7  | M   | 45       | 32.7        | 56.4     | 67.8    | 73.4    | 5.45      | 1.86      | 0.95        | 3.41        | 5.8         | 387.43     | +    | +    | –      | 5       |
| 8  | M   | 34       | 25.4        | 30.7     | 92.7    | 42.7    | 4.86      | 1.44      | 1.26        | 2.76        | 4.3         | 478.7      | –    | –    | 2       |
| 9  | M   | 53       | 23.9        | 25       | 44.7    | 67.5    | 4.43      | 1.64      | 1.41        | 2.78        | 5.8         | 407.5      | –    | –    | 1       |
| 10 | M   | 48       | 23.7        | 24.6     | 61.8    | 55.4    | 4.93      | 1.57      | 1.27        | 2.64        | 5.5         | 421.7      | –    | –    | 1       |
| 11 | M   | 31       | 21.5        | 49       | 51.7    | 78.6    | 5.74      | 1.87      | 1.56        | 2.86        | 4.9         | 367.3      | –    | –    | 3       |
| 12 | M   | 54       | 23.9        | 8.7      | 51.3    | 27.8    | 4.51      | 1.34      | 1.54        | 2.47        | 6.3         | 398.7      | –    | +    | 2       |
| 13 | M   | 48       | 23.1        | 11.9     | 48.7    | 37.4    | 4.61      | 1.56      | 1.31        | 2.54        | 4.9         | 367.1      | –    | –    | 0       |
| 14 | M   | 52       | 16.3        | 35.7     | 47.8    | 65.8    | 4.57      | 1.68      | 1.45        | 2.55        | 4.5         | 417.2      | –    | +    | 1       |
| 15 | M   | 49       | 24.2        | 33.7     | 61.8    | 55.4    | 4.93      | 1.27      | 1.26        | 2.76        | 5.1         | 373.2      | –    | –    | 1       |
| 16 | M   | 29       | 22.1        | 38.5     | 37.4    | 44.5    | 4.6       | 1.37      | 1.36        | 2.89        | 4.6         | 376.8      | –    | –    | 0       |

Note: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; BMI, body mass index; FBG, fasting blood glucose; GGT, γ-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; TC, total cholesterol; Tri, Triglycerides; UA, uric acid.
analysis of gene expression in liver tissue of patients with MAFLD and in normal controls, we identified specific differentially expressed genes by comparing this list with the genes identified in this study, so as to further illustrate the importance of these overlapping genes in the pathogenesis of MAFLD.

Data are presented as means ± standard error (SEM). All data analyses were performed using Prism 8.3.0 (GraphPad Software Inc., San Diego, CA, United States). The raw data from each individual experiment were evaluated using an unpaired two-tailed t-test with 95% confidence interval (CI) in Prism. For data sets that did not pass the D'Agostino and Pearson omnibus normality test (α = 0.05), differences were evaluated using a two-tailed unpaired nonparametric Mann–Whitney test with 95% CI.

RESULTS

FXR-KO Promoted the Development of MAFLD in Mice, but There Were no Significant Differences in FXR Expression Among MAFLD Patients

To investigate the involvement of FXR in MAFLD, we used FXR<sup>−/−</sup> and WT mice fed a HFD for 16 weeks to construct MAFLD models (Figures 1A,B). A shown in Figure 1C, the degree of steatosis and the ballooning of fat droplets were intensified in FXR<sup>−/−</sup> MAFLD mice compared to WT MAFLD mice. Next, we analyzed the expression of FXR in liver tissues of nine normal controls and seven patients with a pathological diagnosis of MAFLD. There were no significant differences in FXR expression between the liver tissue of the MAFLD and control groups (Figure 1D p > 0.05). Consistent with a previous study, inhibition of FXR increased the degree of steatosis in animal models of MAFLD (Ma et al., 2013), which indicated inhibition of FXR was indeed involved in the pathogenesis of MAFLD. However, in the seven patients with MAFLD, we did not identify a significant relationship between FXR expression and MAFLD. Therefore, changes in FXR expression may not necessarily be associated with the onset of MAFLD.

To obtain further insight into steatohepatitis and to explore the pathogenesis of MAFLD at the gene level, we examined the transcriptional regulation of genes implicated in lipogenesis, β-oxidation, and lipolysis in the liver by previous studies (Correia et al., 2015). FXR-KO enhanced the expression of lipogenesis genes (PPAR<sub>γ</sub>, Cd36, Fasn, Pklr, p < 0.05), decreased the expression of β-Oxidation genes (Creb3L3,
SLc25a29, \( p < 0.05 \) and lipolysis gene (Ces1g, \( p < 0.05 \)) (Figure 2A). We identified similar changes in liver gene expression in patients with MAFLD (Figure 2B). Therefore, changes in gene expression could represent driving factor of MAFLD. In mice, FXR deficiency resulted in an imbalance of liver lipid metabolism, which worsened lipid accumulation in the liver and further developed into steatohepatitis. In humans, FXR expression did not differ significantly across the 16 liver tissue samples. There may be a change in FXR protein activity, however, in addition to FXR, other genes or pathways which might play an important role in the pathogenesis of MAFLD have not yet been identified and need to be further explored.

Pathway Analysis of Overlapping Genes and Differentially-Expressed Genes

To further explore the regulation of MAFLD, we compared the transcriptomic analysis of differentially expressed genes from liver tissues of three FXR-KO mice with MAFLD and three WT mice \( [p < 0.05, \log_2 \text{fold change} \geq 0.5 \text{ or } \leq -0.5] \) (Supplementary Table S1), the same transcriptomic analysis was applied to liver tissues of seven patients with MAFLD and nine normal controls \( [p < 0.05, \log_2 \text{fold change} \geq 0.5 \text{ or } \leq -0.5] \) (Supplementary Table S2). By comparing the two groups of differentially expressed genes, we identified 134 overlapping genes (Supplementary Table S3; Figure 3A). The heatmap shows Pearson’s correlation analysis of the expression data of the overlapping genes of liver tissues of MAFLD patients versus controls (Figure 3B). STRING and Cytoscape network analysis of the 134 overlapping genes is shown in Figure 3C.

DAVID was used for the GO and KEGG enrichment analysis of overlapping genes. The pathways and functions are listed in Table 2 \( (p < 0.05) \). The results suggested that these genes were enriched in metabolic pathways, retinol metabolism, oxidation-reduction process, lipid metabolic process, glucose homeostasis, and in insulin secretion. Next, we employed Cytoscape for PPI enrichment analysis to further understand protein interactions and used MCODE to identify densely connected network components. A list of important genetic components in the PPI network is shown in Figure 4A. Metascape was used for pathway and enrichment analyses for each MCODE component. The results showed that the biological functions of the MCODE components consisted of retinol metabolism, phase I-functionalization reactions of compounds, regulation of cell cycle processes, and cell division (Supplementary Table S4).

Many of these overlapping genes have been reported to play an important role in lipid metabolism, which means these genes may be related to the onset of MAFLD. These findings suggested that our method of integrated analysis was reliable and feasible for identifying new regulating genes and pathways in MAFLD.

To discover new target genes and pathways unrelated to FXR, excluding overlapping genes, we obtained 1,124 differentially expressed genes from transcriptomic analysis of liver tissues of MAFLD patients vs. controls \( [p < 0.05, \log_2 \text{fold change} \geq 0.5 \text{ or } \leq -0.5] \) (Supplementary Table S5). We used Metascape to conduct GO and KEGG enrichment analyses (Supplementary Table S6; Figure 4B) (Zhou et al., 2019). The top 20 significant pathways and functions are listed in accordance with their \( p \)-values in Figure 4B. The results suggested that these genes are involved in monocarboxylic acid metabolic processes, regulation of lipid metabolic processes, carbohydrate metabolic processes, the PPAR signaling pathway, fatty acid transmembrane transport, and triglyceride metabolic processes. We also employed Cytoscape for PPI enrichment analysis to

---

**FIGURE 2** The expression of lipid metabolism genes was altered in patients/mice with MAFLD. (A,B) Expression of genes involved in de novo lipogenesis, \( \beta \)-oxidation, and lipolysis measured by qPCR. (*\( p < 0.05 \); **\( p < 0.01 \); ***\( p < 0.001 \).

---

**Table 2** \( (p < 0.05) \). The results suggested that these genes were enriched in metabolic pathways, retinol metabolism, oxidation-reduction process, lipid metabolic process, glucose homeostasis, and in insulin secretion. Next, we employed Cytoscape for PPI enrichment analysis to further understand protein interactions and used MCODE to identify densely connected network components. A list of important genetic components in the PPI network is shown in Figure 4A. Metascape was used for pathway and enrichment analyses for each MCODE component. The results showed that the biological functions of the MCODE components consisted of retinol metabolism, phase I-functionalization reactions of compounds, regulation of cell cycle processes, and cell division (Supplementary Table S4). Many of these overlapping genes have been reported to play an important role in lipid metabolism, which means these genes may be related to the onset of MAFLD. These findings suggested that our method of integrated analysis was reliable and feasible for identifying new regulating genes and pathways in MAFLD.

To discover new target genes and pathways unrelated to FXR, excluding overlapping genes, we obtained 1,124 differentially expressed genes from transcriptomic analysis of liver tissues of MAFLD patients vs. controls \( [p < 0.05, \log_2 \text{fold change} \geq 0.5 \text{ or } \leq -0.5] \) (Supplementary Table S5). We used Metascape to conduct GO and KEGG enrichment analyses (Supplementary Table S6; Figure 4B) (Zhou et al., 2019). The top 20 significant pathways and functions are listed in accordance with their \( p \)-values in Figure 4B. The results suggested that these genes are involved in monocarboxylic acid metabolic processes, regulation of lipid metabolic processes, carbohydrate metabolic processes, the PPAR signaling pathway, fatty acid transmembrane transport, and triglyceride metabolic processes. We also employed Cytoscape for PPI enrichment analysis to
investigate protein interactions and used the MCODE algorithm to identify densely connected network components. A list of important genetic components in the PPI network is shown in Figure 4C. The 11 most important MCODE components were selected, after which pathway and enrichment analyses were applied by Metascape to each MCODE component (Supplementary Table S7). The results showed that the biological functions of the MCODE components included protein binding, cell division, rRNA processing, the PPAR signaling pathway, fatty acid metabolism, fatty acid degradation, transmembrane-ephrin receptor activity, metabolic pathways, and DNA binding. These pathways and biological functions may play an important role in the pathogenesis of MAFLD. The identification of a new regulator of lipid metabolism associated with MAFLD, would be of great significance in improving the understanding of the pathogenesis of MAFLD.

Expression of BHMT2 and PKLR was Elevated in Patients With MAFLD

Next, we verified the reliability of the above differentially expresses gene with datasets from the GEO database, choosing the GSE48452 dataset from the study of “Human liver biopsy of different phases from control to NASH” (Ahrens et al., 2013). A total of 14 healthy controls, 14 steatosis (SS) samples, and 18 nonalcoholic steatohepatitis (NASH) samples were included in the GSE48452 dataset (Liu et al., 2020). According to the transcriptomic analysis, we identified the differentially expressed genes in liver tissues of the GSE48452 dataset.
TABLE 2 | DAVID functional annotation for overlapping genes.

| Term                                      | Count | p-value  | Genes                                                                 |
|-------------------------------------------|-------|----------|----------------------------------------------------------------------|
| **A. KEGG analysis**                      |       |          |                                                                      |
| Metabolic pathways                        | 22    | 0.001255141 | DMGDH, SDS, PKLR, GDA, TAT, HDC, AMT, MSMO1, OMBL, PLA2G7, DPM2, CYP26A1, CYP2A6, CYP2B6, ETNK2, EHHADH, ALDH1A1, RDH16, MAN1C1, NPPLA3, UPP1, UGT1A9 |
| Biosynthesis of antibiotics               | 8     | 0.002538832  | SDS, PKLR, TAT, EHHADH, AMT, MSMO1, OMBL, PLA2G7                     |
| Retinol metabolism                        | 6     | 2.37E-04   | CYP26A1, CYP2A6, CYP2B6, ALDH1A1, RDH16, UGT1A9                    |
| TNF signaling pathway                     | 5     | 0.014646592  | SOCS3, BCL3, MAPK98, ICAM1, MAP2K6                                 |
| Glycine, serine, and threonine metabolism | 3     | 0.046470689  | DMGDH, SDS, AMT                                                  |

| **B. GO-BP analysis**                     |       |          |                                                                      |
| Apoptotic process                         | 11    | 0.007898886  | CSRNP1, SDMA6A, PEG10, ITGB2, CDK1, CKAP2, PIM1, PIM3, MAPK8, GADD45G, MAP2K6 |
| Oxidation-reduction process               | 11    | 0.010507529  | CYP39A1, DMGDH, CYP2B6, CYP2A6, CYP2B6, ALDH1A1, CYP4A11, RDH16, MSMO1, KCNAB2, CYP46A1 |
| Xenobiotic metabolic process              | 6     | 2.48E-04   | SULT1B1, CYP2B6, CYP26A1, CMLN, UGT1A9, CYP46A1                   |
| Lipid metabolic process                   | 6     | 0.031793828  | SLC5A6, SLC14A1, ABCA2, SLC16A12, SLC25A25, TOMM40L              |
| Steroid metabolic process                 | 5     | 0.033337445  | EHHADH, MAN1C1, UGT1A9, HDH3, SULF2                             |
| Response to mechanical stimulus           | 4     | 0.00884836  | P2RX7, TRPV4, IGBPBP2, PIEZ2                                   |
| Response to glucocorticoid                | 4     | 0.011524629  | IL1RN, DSP1, TAT, IGBPBP2                                       |
| Glucose homeostasis                       | 4     | 0.03653111  | PPF1R9, OAS1, TRPV4, PKD4                                         |
| Insulin secretion                         | 3     | 0.02096581  | IL1RN, ILDR2, RAPgef4                                           |
| Epoxigenase P450 pathway                  | 3     | 0.007306425  | CYP2A6, CYP2B6, CYP4A11                                          |
| Regulation of G protein coupled receptor protein signaling pathway | 3     | 0.032082211  | RCBB, RGS16, RAMP1                                              |
| Cellular amino acid metabolic process     | 3     | 0.033814942  | SDS, TAT, HDC                                                   |
| Extrinsic apoptotic signaling pathway     | 3     | 0.036762654  | P2RX7, TNFRSF12A, GOSZ                                          |
| Receptor internalization                  | 3     | 0.038371848  | ITGB2, CD36, RAMP1                                              |
| T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell | 2     | 0.021463309  | APBB1P, ICAM1                                                   |

(Supplementary Table S8). In the GSE63067 dataset, differentially expressed genes were stratified according to different stages of NAFLD, and included genome-wide expression patterns from two cases of human steatosis and nine cases of human NASH and seven healthy controls (Supplementary Table S9). These two lists of differentially expressed genes were compared with the 134 overlapping genes, and two overlapping genes were identified: BHMT2 and PKLR (Figures 5A,B). Our results of the transcriptional analysis comparing liver tissues of MAFLD patients and controls indicated the expression of BHMT2 and PKLR was elevated in MAFLD patients (p < 0.05) (Figure 5C).

To further confirm the changes in the expression of BHMT2 and PKLR in the liver of patients with MAFLD, we also performed immunohistochemical staining using these 16 liver tissue samples. The results showed that the expression of BHMT2 and PKLR was significantly increased in liver tissues of MAFLD patients compared to controls (Figures 5D,E).

Then, we explored the functions of BHMT2 and PKLR in MAFLD. We analyzed the clinical characteristics of seven patients with NASH and nine normal controls. The results showed that the clinical parameters BMI, TC, TG, ALT, ALP, and GGT of patients with MAFLD were higher than those of controls (Figure 6A). According to the latest clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD (Eslam et al., 2020b), these indicators play an important role in the diagnosis of MAFLD. We questioned whether there was any relationship between the change in these clinical indicators with the expression level of BHMT2 and PKLR. Pearson’s correlation analysis was performed and the results indicated that the expression levels of BHMT2 and PKLR were positively correlated with the serum content of TC, TG, and LDL-C (Figure 6B). Overall, these findings suggested that BHMT2 and PKLR could be involved in the pathogenesis of MAFLD.

BHMT2 May be Involved in Hepatocyte Lipid Metabolism by Regulating the Expression of PPARγ In Vitro.

Previous studies have indicated that PKLR plays an important role in the pathogenesis of MAFLD (Yki-Järvinen, 2014; Byrne and Targher, 2015). We questioned what role BHMT2 could play in the development of MAFLD. To further verify the function of BHMT2 in lipid metabolism in the liver, we modified the expression of BHMT2 in L02 cells by RNAi.
FIGURE 4 | Comprehensive analysis of differentially expressed genes in the transcriptomic analysis of patients with MAFLD vs. control subjects using Metascape and Cytoscape. (A) The four significant MCODE components form the PPI network of overlapping genes. (B) Bar graphs showing the top 20 significantly enriched biological processes and pathways associated with MAFLD differently expressed genes excluding overlapping genes. (C) The top 11 significant MCODE components from the PPI network of MAFLD differently expressed genes excluding overlapping genes. The MCODE algorithm was applied to this network to identify neighborhoods where proteins are densely connected. Each node represents a protein, and the edge between nodes represents the interaction between two connected proteins.
When BHMT2 was downregulated, the presence of OA (oleic acid) + PA (palmitic acid)-induced lipid droplets (LD) was significantly decreased (Figures 7A,B). We used CGI-58 as lipid drop markers for the western blotting semi-quantitatively analysis, and the results showed that inhibition of BHMT2 expression reduced the expression of CGI-58. It further confirmed the effect of BHMT2 on lipid metabolism in vitro (Figure 7C). The results of real-time PCR revealed that inhibition of BHMT2 expression resulted in decreased PPAR expression (Figure 7D), which confirmed that
BHMT2 may be involved in the metabolism of hepatocyte lipids by regulating the expression of PPARG in vitro.

**DISCUSSION**

In this study, using a unique analytical approach, we comprehensively analyzed the regulatory factors of MAFLD at the genome-wide level. We compared the differentially expressed genes in FXR-KO mice and patients with MAFLD and their respective controls, and identified 134 overlapping genes. These genes were found to be involved in important signaling pathways and in lipid metabolism, as identified by pathway analysis, which also demonstrated the reliability of our unique analytical method. Using a similar approach, in conjunction with the GEO database, we identified two specific overlapping genes BHMT2 and PKLR from an independent human dataset of MAFLD. Herein, we demonstrated that BHMT2 is a newly identified regulator of lipid metabolism associated with MAFLD.

In previous studies, genome-wide association studies identified dozens of genes with multiple polymorphisms that were associated with the increased risk of developing fatty liver disease in specific populations, including PPARG, PNPLA3, TM6SF2, PCSK9, HSD17B13, FXR, GCKR, APOB, LPIN1,
UCP2, IFLN4, and PKLR (Yu et al., 2016; Lee et al., 2017; Schumacher and Guo, 2019). Related studies have shown that FXR plays a precise role in the occurrence and development of MAFLD. FXR agonism has been shown to be a promising pharmacological target, FXR activation is protective against liver inflammation associated with NASH (Armstrong and Guo, 2017). The expression of factors in both the adaptive and innate immune response in the liver is regulated in an FXR-dependent and independent manner. In human hepatocytes, FXR upregulated peroxisome proliferator-activated receptor alpha (PPARα) levels, which subsequently increased fatty acid oxidation (Verbeke et al., 2016). Furthermore, mouse livers deficient in FXR, exhibited elevated serum cholesterol levels compared to WT mice when fed a high-cholesterol diet (Pineda Torra et al., 2003).

We used FXR-KO mice to construct MAFLD models. The results of H&E staining indicated that decreasing the expression of FXR in the liver could lead to the development of MAFLD. In humans, FXR expression was not significantly different between MAFLD and controls, which could reflect a change in FXR protein activity, and conversely may also indicate that changes in FXR expression may not be necessarily associated with the onset of MAFLD. Besides FXR, other genes or pathways have yet to be identified.

We performed a transcriptomic analysis using liver tissues from FXR-KO mice and MAFLD patients, and identified 134 overlapping differentially expressed genes in the two models. Pathway analysis suggested that these genes were enriched in metabolic pathways, retinol metabolism, oxidation-reduction processes, lipid metabolic processes, glucose homeostasis, and in insulin secretion. The PPI enrichment analysis showed that the biological functions of the MCODE components consisted of retinol metabolism, phase I functionalization modification of compounds, regulation of cell cycle processes, and cell division. FXR is associated with several signaling pathways besides lipid metabolism, which indicates that changes in these signal pathways and genes are downstream events or results that lead to MAFLD. Therefore, the overlapping genes may play an important role in the pathogenesis of MAFLD, which needs to be further studied.

To identify new target genes and pathways that are independent of the FXR pathway, we analyzed the pathway enrichment involving the identified 1,124 differentially expressed genes. Our results suggested that these genes were involved in monocarboxylic acid metabolic processes, regulation of lipid metabolic processes,
carbohydrate metabolic processes, the PPAR signaling pathway, fatty acid transmembrane transport, and triglyceride metabolic process. The PPI enrichment analysis showed that the biological functions of the MCODE components involved protein binding, cell division, rRNA processing, the PPAR signaling pathway, fatty acid metabolism, fatty acid degradation, transmembrane-ephrin receptor activity, metabolic pathways, and DNA binding. These pathways and biological functions may also play an important role in the pathogenesis of MAFLD.

We next combined the GEO databases GSE48452 and GSE63067 from NCBI, and identified BHMT2 and PKLR among the 134 overlapping genes. Our own transcriptional analysis showed that the expressions of BHMT2 and PKLR was elevated in MAFLD. Immunofluorescence staining further showed that the expression of BHMT2 and PKLR was significantly increased in MAFLD compared to controls. Previous studies showed that the protein encoded by pyruvate kinase L/R (PKLR) is a kinase that catalyzed the transphosphorylation of phosphoenolpyruvate into pyruvate and ATP, which are the rate-limiting steps of glycolysis. Defects in this enzyme, due to gene mutations or genetic variations, are common causes of chronic hereditary nonspherocytic hemolytic anemia. Most importantly, the modulation of these genes affects key metabolic pathways associated with lipid metabolism (i.e., steroid biosynthesis, the PPAR signaling pathway, fatty acid synthesis, and oxidation) and have been proposed to be involved in the progression of MAFLD. For example, inhibition of PKLR led to decreased glucose uptake and decreased mitochondrial activity in HepG2 cells (Schmitt et al., 2015). In vivo knockdown experiments of PKLR improved both steatosis and insulin resistance (Liu et al., 2019). Furthermore, PKLR induced mitochondrial stress in both steatosis and fibrosis models, and silencing PKLR relieved this stress and promoted the resolution of NAFLD/NASH (Chella Krishnan et al., 2018). Therefore, PKLR could be considered an efficient treatment strategy for MAFLD.

The protein encoded by BHMT2 is a methyl transferase that can catalyze the transfer of the methyl group from betaine to homocysteine. Anomalies in homocysteine metabolism have been implicated in disorders ranging from vascular disease to neural tube birth defects such as spina bifida (Chella Krishnan et al., 2021). BHMT2 is involved in adolescent obesity by affecting the metabolism of amino acids, that may be candidate genes in the etiology of obesity (Mostowska et al., 2010). BHMT2 has been reported to be downregulated during both short- and long-term weight loss (Aguilera et al., 2015; Bollepalli et al., 2018). BHMT overexpression increases PtdCho synthesis, leading to reduced lipid accumulation in the liver, while BHMT deficiency leads to fatty liver (Ji et al., 2008). In addition, BHMT−/− mice presented reduced adiposity, enhanced insulin sensitivity, glucose tolerance, and increased whole body energy expenditure (Teng et al., 2011; Teng et al., 2012). BHMT may be related to lipid metabolism, but there have been no reports indicating that BHMT2 is involved in the lipid metabolism observed in MAFLD pathogenesis.

In the present study, the evaluation of the clinical characteristics showed that the BMI, TC, Tri, ALT, ALP, and GGT levels of patients with MAFLD were higher than those of controls. Pearson’s correlation analysis indicated that BHMT2 and PKLR were positively correlated with serum levels of TG, TC, and LDL-C. Similarly, our RNAi studies and western blotting showed that reducing BHMT2 expression could significantly reduce hepatocyte LD accumulation in vitro. Real-time PCR results showed that inhibition of BHMT2 expression resulted in decreased PPAR expression. The PPAR signaling pathway is an important pathway of lipid metabolism plays an crucial role in the pathogenesis of MAFLD (Pawlak et al., 2014; Montagner et al., 2016). Peroxisome proliferator-activated receptor (PPAR)α, β/δ, and γ modulate lipid homeostasis. Whole-body and hepatocyte-specific PPARα-deficient mice develop aggravated liver steatohepatitis when fed a HFD and or a methionine and choline-deficient diet (Wang et al., 2020). Activation of PPARγ/δ may prevent dyslipidemia, insulin resistance, obesity, and NAFLD (Palomer et al., 2018). PPARγ is highly expressed in adipose tissue and macrophages, and plays important roles in adipogenesis, lipid metabolism, insulin sensitivity, and immune regulation (Ahmadian et al., 2013). When PPARγ is ectopically overexpressed in hepatocytes, lipid droplets emerge. Adenovirus-mediated overexpression of PPARγ2 in hepatocytes increased hepatosteatosis and hepatocyte-specific disruption of PPARγ gene (PPARG) decreased liver steatosis in PPARγ−/− mice (Yu et al., 2003). Therefore, BHMT2 may be involved in hepatocyte lipid metabolism by regulating the expression of PPARG in vitro. However, the detailed mechanisms involved in the reduction of LD reducing induced by BHMT2 deficiency requires further study.

RNA Interference

The RNA oligos complementary to the BHMT2 gene and non-target sites were obtained from GenePharma (Shanghai, China). OligoRNA was introduced into L02 cells by transfection with Lipofectamine 2000 reagent (Invitrogen, United States) according to the protocol provided by the manufacturer. The human liver cell line L02 (Pang et al., 2000) was obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and was cultured in RPMI-1640 medium containing 20% FBS (Invitrogen, United States) with 4 mM of L-glutamine, and 10 μg/ml of penicillin and streptomycin at 37°C, in an atmosphere of 5% CO2.

CONCLUSION

In summary, our study comprehensively analyzed the regulatory factors of MAFLD at the genome-wide level by comparing the differentially expressed genes of FXR-KO mice and patients with MAFLD. Through this unique analysis method, we identified many new target genes and pathways that may potentially play an important role in the pathogenesis of MAFLD. Most importantly, we demonstrated that BHMT2 is a new regulator of lipid metabolism and is involved in MAFLD pathogenesis. Overall, our results may provide a better understanding of the pathogenesis of MAFLD and thus provide new targets for the treatment of MAFLD.
DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: GEO, GSE183229.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The ethics committee of the Second Xiangya Hospital of Central South University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by The ethics committee of the Second Xiangya Hospital of Central South University.

AUTHOR CONTRIBUTIONS

Aguilera, C., Gomez-Llorente, C., Tofe, I., Gil-Campos, M., Cañete, R., and Gil, Á. (2015). Genome-wide Expression in Visceral Adipose Tissue from Obese Prepubertal Children. ijms 16 (4), 7723–7737. doi:10.3390/ijms16047723 Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., et al. (2013). PPARy Signaling and Metabolism: the Good, the Bad and the Future. Nat. Med. 19 (5), 557–566. doi:10.1038/nm.3159 Ahrens, M., Ammerpohl, O., von Schönfels, W., Kolarova, J., Bens, S., Itzel, T., et al. (2013). DNA Methylation Analysis in Nonalcoholic Fatty Liver Disease Suggests Distinct Disease-specific and Remodeling Signatures after Bariatric Surgery. Cell Metab. 18 (2), 296–302. doi:10.1016/j.cmet.2013.07.004 Armstrong, L. E., and Guo, G. L. (2017). Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Curr. Pharmacol. Rep. 3 (2), 92–100. doi:10.1080/ s40495-017-0085-2 Bollepalli, S., Kaye, S., Heinonen, S., Kaprio, J., Rissanen, A., Virtanen, K. A., et al. (2018). Subcutaneous Adipose Tissue Gene Expression and DNA Methylation Respond to Both Short- and Long-Term Weight Loss. Int. J. Obes. 42 (3), 412–423. doi:10.1038/ijo.2017.245 Buzzetti, E., Pinzani, M., and Toschatzis, E. A. (2016). The Multiple-Hit Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD). Metabolism 65 (8), 1038–1048. doi:10.1016/j.metabol.2015.12.012 Byrne, C. D., and Targher, G. (2015). NAFLD: A Multisystem Disease. J. Hepatol. 62 (1 Suppl. 1), S47–S64. doi:10.1016/j.jhep.2014.12.012 Chella Krishnan, K., Floyd, R. R., Sabir, S., Jayasekara, D. W., Leon-Mimila, P. V., Jones, A. E., et al. (2021). Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-specific Manner. Cell Mol. Gastroenterol. Hepatol. 11 (2), 389–406. doi:10.1016/j.jcmgh.2020.09.004 Chella Krishnan, K., Kurt, Z., Barrere-Cain, R., Sabir, S., Das, A., Floyd, R., et al. (2018). Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease. Cell Syst. 6 (1), 103–115. e107. doi:10.1016/j.cels.2017.12.006 Correira, J. C., Massart, J., de Boer, J. F., Porsmyr-Palmertz, M., Martinez-Redondo, V., Agudelo, L. Z., et al. (2015). Bioenergetic Cues Shift FXR Splicing towards FXRα2 to Modulate Hepatic Lipolysis and Fatty Acid Metabolism. Mol. Metab. 4 (12), 891–902. doi:10.1016/j.molmet.2015.09.005 Eslam, M., Newcombe, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., et al. (2020a). A New Definition for Metabolic Dysfunction-associated Fatty Liver, JY, and XL: performed the pathological and statistical analysis; JT and ZS: provided general guidance, concept development; JL: performed the overall supervision, study design, data analysis, obtained funding support, and manuscript preparation, and finalization.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 82070679), Hunan Province Science and Technology Grant (Grant No. 2019GK5010), Natural Science Foundation of Hunan Province, China (Grant No. 2019JJ50870), and Research Grant of Tianqing for Liver Diseases (TQGB20210181).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.741710/full?supplementary-material
Mostowska, A., Hozysz, K. K., Biedziak, B., Misiaik, J., and Jagodziński, P. P. (2010). Polymorphisms Located in the Region Containing BHMT and BHMT2 Genes as Maternal Protective Factors for Orofacial Clefts. *Eur. J. Oral Sci.* 118 (4), 325–332. doi:10.1111/j.1600-0722.2010.00757.x

Ogawa, Y., Yoneda, M., Kobayashi, T., Honda, Y., Kessoku, T., Imaio, K., et al. (2019). Present and Emerging Pharmacotherapies for Non-alcoholic Steatohepatitis in Adults. *Expert Opin. Pharmacother.* 20 (1), 69–82. doi:10.1080/14656566.2018.1543403

Palomer, X., Barroso, E., Pizarro-Delgado, J., Peña, L., Botteri, G., Zarei, M., et al. (2018). Pparfl/R: A Key Therapeutic Target in Metabolic Disorders. *Ijms* 19 (3), 913. doi:10.3390/ijms19030913

Pang, E., Wong, N., Lai, P. B.-S., To, K.-F., Lau, J. W.-Y., and Johnson, P. J. (2000). Schmitt, J., Kong, B., Stieger, B., Tschopp, O., Schultze, S. M., Rau, M., et al. (2015). Protective Effects of Farnesoid X Receptor (FXR) on Hepatic Lipid Accumulation Are Mediated by Hepatic FXR and Independent of Intestinal FGFR5 Signal. *Liver Int.* 35 (4), 1133–1144. doi:10.1111/liv.12456

Pawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., et al. (2014). The Transrepressive Activity of Peroxisome Proliferator-Activated Receptor Alpha Is Necessary and Sufficient to Prevent Liver Fibrosis in Mice. *Hepatology* 60 (5), 1593–1606. doi:10.1002/hep.27297

Pineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.-C., and Staels, B. (2011). Deletion of Betaine-Homocysteine S-Methyltransferase in Mice Perturbs Choline and 1-Methyl-1-Homocysteine Metabolism, Resulting in Fatty Liver and Hepatocellular Carcinomas. *J. Biol. Chem.* 286 (42), 36258–36267. doi:10.1074/jbc.M111.265348

Teng, Y.-W., Ellis, J. M., Coleman, R. A., and Zeisel, S. H. (2012). Mouse Betaine-Homocysteine S-Methyltransferase Deficiency Reduces Body Fat via Increasing Energy Expenditure and Impairing Lipid Synthesis and Enhancing Glucose Oxidation in white Adipose Tissue. *J. Biol. Chem.* 287 (20), 16187–16198. doi:10.1074/jbc.M111.303255

Teng, Y.-W., Madhenti, M. G., Garrow, T. A., and Zeisel, S. H. (2011). Deletion of Betaine-Homocysteine S-Methyltransferase in Mice Perturbs Choline and 1-Carbon Metabolism, Resulting in Fatty Liver and Hepatocellular Carcinomas. *J. Biol. Chem.* 286 (42), 36258–36267. doi:10.1074/jbc.M111.265348

Tilly, H., and Moschen, A. R. (2010). Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: the Multiple Parallel Hits Hypothesis. *Hepatology* 52 (5), 1836–1846. doi:10.1002/hep.24001

Tully, D. C., Rucker, P. V., Chianelli, D., Williams, J., Vidal, A., Alper, P. B., et al. (2017). Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). *J. Med. Chem.* 60 (24), 9960–9973. doi:10.1021/acs.jmedchem.7b00907

Verbeke, L., Manmaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., et al. (2016). FXR Agonist Obeticholic Acid Reduces Hepatic Inflammation and Fibrosis in a Rat Model of Toxic Cirrhosis. *Sci. Rep.* 6, 33453. doi:10.1038/srep33453

Wang, Y., Nakajima, T., Gonzalez, F. J., and Tanaka, N. (2020). PPARs as Metabolic Regulators in the Liver: Lessons from Liver-specific PPAR-Null Mice. *Ijms* 21 (6), 2061. doi:10.3390/ijms21062061

Yki-Järvinen, H. (2014). Non-alcoholic Fatty Liver Disease as a Cause and a Consequence of Metabolic Syndrome. *Lancet Diabetes Endocrinol.* 2 (11), 901–910. doi:10.1016/s2213-8587(14)70032-4

Yu, J., Marsh, S., Hu, J., Feng, W., and Wu, C. (2016). The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. *Gastroenterol. Res. Pract.* 2016, 1–13. doi:10.1155/2016/2862173

Yu, S., Matsusue, K., Kashireddy, P., Cao, W.-Q., Yeldandi, V., Yeldandi, A. V., et al. (2003). Adipocyte-specific Gene Expression and Adipogenic Steatosis in the Mouse Liver Due to Peroxisome Proliferator-Activated Receptor γ1 (PPARγ1) Overexpression. *J. Biol. Chem.* 278 (1), 498–505. doi:10.1074/jbc.M210062200

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., et al. (2019). Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets. *Nat. Commun.* 10 (1), 1523. doi:10.1038/s41467-019-09234-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Ma, Tan, Li, Fan, Chen, Bin, Zhou, Yi, Luo, Tan, Si and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.